Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pierre Fumoleau

Showing results (71-80 of 110) with videos related to

Pageof 11
Sort By:
Contrast Media & Molecular Imaging|January 11, 2019
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer ModelPierre-Simon Bellaye, Alexandra Oudot, Jean-Marc Vrigneaud, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 23, 2016
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast CancerOlivier Humbert, Jean-Marc Riedinger, Jean-Marc Vrigneaud, et al.
Oncology and Therapy|March 7, 2017
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER StudyVéronique Diéras, Thomas Bachelot, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJoyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
Anti-Cancer Drugs|November 1, 2006
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosisCécile Molucon-Chabrot, Nicolas Isambert, Laurent Benoit, et al.
Plos One|July 17, 2018
FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCISTEdouard Depardon, Salim Kanoun, Olivier Humbert, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study groupJacques Bonneterre, Henri Roché, Pierre Kerbrat, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2022
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approachManon Reda, Pauline Macaire, Hélène Bellio, et al.
Oncogene|May 18, 2005
Identification of molecular apocrine breast tumours by microarray analysisPierre Farmer, Herve Bonnefoi, Veronique Becette, et al.
Pageof 11

Showing results (71-80 of 110) with videos related to

Sort By:
Pageof 11
Contrast Media & Molecular Imaging|January 11, 2019
Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer ModelPierre-Simon Bellaye, Alexandra Oudot, Jean-Marc Vrigneaud, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 23, 2016
18F-FDG PET-Derived Tumor Blood Flow Changes After 1 Cycle of Neoadjuvant Chemotherapy Predicts Outcome in Triple-Negative Breast CancerOlivier Humbert, Jean-Marc Riedinger, Jean-Marc Vrigneaud, et al.
Oncology and Therapy|March 7, 2017
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER StudyVéronique Diéras, Thomas Bachelot, Mario Campone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 18, 2002
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial resultsJoyce O'Shaughnessy, David Miles, Svetislava Vukelja, et al.
Anti-Cancer Drugs|November 1, 2006
Feasibility of using intraperitoneal epinephrine and cisplatin in patients with advanced peritoneal carcinomatosisCécile Molucon-Chabrot, Nicolas Isambert, Laurent Benoit, et al.
Plos One|July 17, 2018
FDG PET/CT for prognostic stratification of patients with metastatic breast cancer treated with first line systemic therapy: Comparison of EORTC criteria and PERCISTEdouard Depardon, Salim Kanoun, Olivier Humbert, et al.
European Journal of Cancer (Oxford, England : 1990)|April 3, 2012
New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trialsThierry Gorlia, Roger Stupp, Alba A Brandes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2004
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study groupJacques Bonneterre, Henri Roché, Pierre Kerbrat, et al.
Cancer Chemotherapy and Pharmacology|January 8, 2022
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approachManon Reda, Pauline Macaire, Hélène Bellio, et al.
Oncogene|May 18, 2005
Identification of molecular apocrine breast tumours by microarray analysisPierre Farmer, Herve Bonnefoi, Veronique Becette, et al.
Pageof 11